Astria Therapeutics Receives Buy Rating Due to Promising Clinical Developments and Strategic Market Positioning
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Astria Therapeutics (ATXS – Research Report), with ...